GUTS · Fractyl Health, Inc. · Webcasts, Transcripts & Audio
$0.97
-0.11 (-9.92%)
At close · Nov 19
Return incl. dividend (before tax)
Play latest call
Q3 2026 earnings call transcript
Going-concern doubt
— flagged Nov 12, 2026
Substantial doubt about the company's ability to continue as a going concern.
“As a result, we have concluded that substantial doubt exists about our ability to continue as a going concern for at least one year after the date that these financial statements are issued.”View the 10-Q filed Nov 12, 2026
Market Cap
$12.67M
Shares
13.26M
Volume · Nov 19
223.24K
Avg daily vol (34 sessions)
804.78K
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Fractyl Health, Inc. Webcasts
Earnings calls, investor updates, investor days and conferences for Fractyl Health, Inc. (GUTS), with available transcripts, audio replays and slides. Earnings calls also include available highlights, earnings releases and periodic filings.
Pull transcripts and briefs through the earnings call transcript API or MCP →
Add these events to your calendar (.ics)
Conference
Investor event
2026-11-12
Fractyl Health, Inc. (GUTS) November 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q3
2026-11-12
Fractyl Health, Inc. (GUTS) Q3 2026 Earnings Call Transcript
Confident tone
Revita pivotal efficacy
12-month data and future milestones
CMS coverage and reimbursement
Diluted EPS
$-1.07
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-09-14
Fractyl Health, Inc. (GUTS) September 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Conference
Investor event
2026-08-12
Fractyl Health, Inc. (GUTS) August 12, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q2
2026-08-10
Fractyl Health, Inc. (GUTS) Q2 2026 Earnings Call Transcript
Confident tone
Revita pivotal trial readout (Remain 1)
GLP-1 market dynamics and off-ramp thesis
Regulatory pathway and FDA engagement
Diluted EPS
$-1.92
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Conference
Investor event
2026-05-14
Fractyl Health, Inc. (GUTS) May 14, 2026 Conference Transcript
No reported result — non-financial event
Audio
Transcript
Slides
Earnings call
FY26 · Q1
2026-05-12
Fractyl Health, Inc. (GUTS) Q1 2026 Earnings Call Transcript
Confident tone
IP portfolio
Pivotal trial execution (Remain One)
GLP-1 market dynamics and post-GLP-1 rebound
Diluted EPS
$0.72
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q4
2026-03-24
Fractyl Health, Inc. (GUTS) Q4 2025 Earnings Call Transcript
Confident tone
Revita dose-response (ablation length)
REMAIN-1 pivotal study design and readout timeline
Regulatory pathway and FDA feedback
Results not yet reported
Audio
Transcript
Slides
8-K10-K
Earnings call
FY25 · Q3
2025-11-12
Fractyl Health, Inc. (GUTS) Q3 2025 Earnings Call Transcript
Confident tone
Revita Clinical Data and Durability
Remain 1 Pivotal Trial Progress
Upcoming Clinical Catalysts and Regulatory Path
Diluted EPS
$-8.46
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q2
2025-08-12
Fractyl Health, Inc. (GUTS) Q2 2025 Earnings Call Transcript
Confident tone
Revita / REMAIN-1 pivotal study and randomized readout
Weight regain after GLP-1 discontinuation (unmet need)
German real-world registry durability data
Diluted EPS
$-6.84
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY25 · Q1
2025-05-13
Fractyl Health, Inc. (GUTS) Q1 2025 Earnings Call Transcript
Confident tone
Remain-1 pivotal enrollment completion
Rejuva / RJVA-001 gene therapy platform
GLP-1 efficacy and durability gap
Diluted EPS
$-5.88
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q4
2025-03-03
Fractyl Health, Inc. (GUTS) Q4 2024 Earnings Call Transcript
Confident tone
Revita / REMAIN-1 pivotal study in weight maintenance
Rejuva gene therapy platform
REVEAL-1 open-label early data
Revenue
$3,000*
▼ 57.1% YoY Gross margin
100.0%
Rev · 6q
Audio
Transcript
Slides
8-K10-K
Earnings call
FY24 · Q3
2024-11-12
Fractyl Health, Inc. (GUTS) Q3 2024 Earnings Call Transcript
Confident tone
GLP-1 limitations and durability concerns
Rejuva gene therapy platform and preclinical data
Revita REMAIN-1 pivotal study for weight maintenance
Revenue
$14,000
▼ 61.1% YoY Diluted EPS
$-5.76
Gross margin
50.0%
Rev · 6q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q2
2024-08-14
Fractyl Health, Inc. (GUTS) Q2 2024 Earnings Call Transcript
Positive tone
Revita Breakthrough Device Designation
REMAIN-1 Weight Maintenance Study
Rejuva Gene Therapy Platform
Revenue
$43,000
▼ 40.3% YoY Diluted EPS
$-4.32
Gross margin
44.2%
Rev · 5q
Audio
Transcript
Slides
8-K10-Q
Earnings call
FY24 · Q1
2024-05-13
Fractyl Health, Inc. (GUTS) Q1 2024 Earnings Call Transcript
Confident tone
Revita Remain-1 Pivotal Study in Obesity
Revitalize-1 Pivotal Trial in Type 2 Diabetes
Rejuva Gene Therapy Platform / RJVA-001
Revenue
$33,000
▲ 560% YoY Diluted EPS
$-2.04
Gross margin
42.4%
Rev · 4q
Audio
Transcript
Slides
8-K10-Q
Showing 1–15 of 15 webcasts
Key facts
CIK
1572616
CUSIP
35168W202
13F (30d)
87 filings
72 filers
Visit website
Investor relations